S&P 500   4,280.15 (+1.73%)
DOW   33,761.05 (+1.27%)
QQQ   330.39 (+1.95%)
AAPL   172.10 (+2.14%)
MSFT   291.91 (+1.70%)
META   180.50 (+1.70%)
GOOGL   121.68 (+2.39%)
AMZN   143.55 (+2.07%)
TSLA   900.09 (+4.68%)
NVDA   187.09 (+4.27%)
NIO   21.11 (+1.39%)
BABA   94.77 (-0.11%)
AMD   100.83 (+2.76%)
MU   65.04 (+4.36%)
T   18.27 (+1.27%)
CGC   3.30 (+4.76%)
GE   79.93 (+1.31%)
F   16.18 (+2.21%)
DIS   121.57 (+3.30%)
AMC   24.44 (-3.97%)
PYPL   101.10 (+2.01%)
PFE   50.11 (+3.77%)
NFLX   249.30 (+2.72%)
S&P 500   4,280.15 (+1.73%)
DOW   33,761.05 (+1.27%)
QQQ   330.39 (+1.95%)
AAPL   172.10 (+2.14%)
MSFT   291.91 (+1.70%)
META   180.50 (+1.70%)
GOOGL   121.68 (+2.39%)
AMZN   143.55 (+2.07%)
TSLA   900.09 (+4.68%)
NVDA   187.09 (+4.27%)
NIO   21.11 (+1.39%)
BABA   94.77 (-0.11%)
AMD   100.83 (+2.76%)
MU   65.04 (+4.36%)
T   18.27 (+1.27%)
CGC   3.30 (+4.76%)
GE   79.93 (+1.31%)
F   16.18 (+2.21%)
DIS   121.57 (+3.30%)
AMC   24.44 (-3.97%)
PYPL   101.10 (+2.01%)
PFE   50.11 (+3.77%)
NFLX   249.30 (+2.72%)
S&P 500   4,280.15 (+1.73%)
DOW   33,761.05 (+1.27%)
QQQ   330.39 (+1.95%)
AAPL   172.10 (+2.14%)
MSFT   291.91 (+1.70%)
META   180.50 (+1.70%)
GOOGL   121.68 (+2.39%)
AMZN   143.55 (+2.07%)
TSLA   900.09 (+4.68%)
NVDA   187.09 (+4.27%)
NIO   21.11 (+1.39%)
BABA   94.77 (-0.11%)
AMD   100.83 (+2.76%)
MU   65.04 (+4.36%)
T   18.27 (+1.27%)
CGC   3.30 (+4.76%)
GE   79.93 (+1.31%)
F   16.18 (+2.21%)
DIS   121.57 (+3.30%)
AMC   24.44 (-3.97%)
PYPL   101.10 (+2.01%)
PFE   50.11 (+3.77%)
NFLX   249.30 (+2.72%)
S&P 500   4,280.15 (+1.73%)
DOW   33,761.05 (+1.27%)
QQQ   330.39 (+1.95%)
AAPL   172.10 (+2.14%)
MSFT   291.91 (+1.70%)
META   180.50 (+1.70%)
GOOGL   121.68 (+2.39%)
AMZN   143.55 (+2.07%)
TSLA   900.09 (+4.68%)
NVDA   187.09 (+4.27%)
NIO   21.11 (+1.39%)
BABA   94.77 (-0.11%)
AMD   100.83 (+2.76%)
MU   65.04 (+4.36%)
T   18.27 (+1.27%)
CGC   3.30 (+4.76%)
GE   79.93 (+1.31%)
F   16.18 (+2.21%)
DIS   121.57 (+3.30%)
AMC   24.44 (-3.97%)
PYPL   101.10 (+2.01%)
PFE   50.11 (+3.77%)
NFLX   249.30 (+2.72%)
NASDAQ:REPL

Replimune Group - REPL Stock Forecast, Price & News

$20.27
+0.47 (+2.37%)
(As of 08/12/2022 12:00 AM ET)
Add
Compare
Today's Range
$19.80
$20.54
50-Day Range
$14.20
$21.15
52-Week Range
$13.05
$35.93
Volume
164,745 shs
Average Volume
316,385 shs
Market Capitalization
$999.45 million
P/E Ratio
N/A
Dividend Yield
N/A
Price Target
$46.00

Replimune Group MarketRank™ Forecast

Analyst Rating
Buy
3.00 Rating Score
Upside/​Downside
126.9% Upside
$46.00 Price Target
Short Interest
Bearish
5.98% of Float Sold Short
Dividend Strength
N/A
Sustainability
-1.28
Upright™ Environmental Score
News Sentiment
-0.45mentions of Replimune Group in the last 14 days
Based on 10 Articles This Week
Insider Trading
Selling Shares
$334,096 Sold Last Quarter
Proj. Earnings Growth
Decreasing
From ($2.85) to ($3.03) Per Share

Overall MarketRank

MarketRank is calculated as an average of available category scores, with extra weight given to analysis and valuation.

2.31 out of 5 stars

Medical Sector

373rd out of 1,117 stocks

Biological Products, Except Diagnostic Industry

57th out of 175 stocks

REPL stock logo

About Replimune Group (NASDAQ:REPL) Stock

Replimune Group, Inc., a biotechnology company, develops oncolytic immuno-gene therapies to treat cancer. It uses its proprietary Immunotherapy platform to design and develop product candidates that are intended to activate the immune system against cancer. The company's lead product candidate is RP1, a selectively replicating version of herpes simplex virus 1, which is in Phase I/II clinical trials for a range of solid tumors; and that is in Phase II clinical trials for patients with cutaneous squamous cell carcinoma. It is also developing RP2, which is in Phase I clinical trials for an anti-CTLA-4 antibody-like protein in order to block the inhibition of the immune response otherwise caused by CTLA-4; and RP3 that is in Phase I clinical trials to express immune-activating proteins that stimulate T cells. Replimune Group, Inc. was founded in 2015 and is headquartered in Woburn, Massachusetts.

Analyst Upgrades and Downgrades

Several equities analysts recently commented on REPL shares. HC Wainwright reiterated a "buy" rating and set a $60.00 price target on shares of Replimune Group in a report on Tuesday, May 24th. SVB Leerink cut their price target on shares of Replimune Group from $48.00 to $37.00 and set an "outperform" rating on the stock in a report on Friday, August 5th. Wedbush cut their price target on shares of Replimune Group from $59.00 to $52.00 and set an "outperform" rating on the stock in a report on Tuesday, May 24th. Finally, Piper Sandler cut their price target on shares of Replimune Group from $52.00 to $44.00 in a report on Thursday, May 19th. Seven equities research analysts have rated the stock with a buy rating, According to MarketBeat, the stock has a consensus rating of "Buy" and an average target price of $46.00.

Replimune Group Stock Up 1.1 %

Shares of Replimune Group stock traded up $0.21 during trading on Friday, hitting $20.01. 419 shares of the company's stock were exchanged, compared to its average volume of 173,427. The company has a current ratio of 19.79, a quick ratio of 19.46 and a debt-to-equity ratio of 0.06. The business has a 50-day simple moving average of $18.46 and a 200-day simple moving average of $17.33. Replimune Group has a 52-week low of $13.05 and a 52-week high of $35.93.

Replimune Group (NASDAQ:REPL - Get Rating) last released its quarterly earnings results on Thursday, August 4th. The company reported ($0.78) EPS for the quarter, missing the consensus estimate of ($0.63) by ($0.15). As a group, equities research analysts forecast that Replimune Group will post -2.85 earnings per share for the current year.

Insider Activity at Replimune Group

In other news, CEO Philip Astley-Sparke sold 9,632 shares of Replimune Group stock in a transaction dated Monday, May 16th. The shares were sold at an average price of $14.59, for a total value of $140,530.88. Following the sale, the chief executive officer now owns 1,401,080 shares in the company, valued at $20,441,757.20. The sale was disclosed in a document filed with the SEC, which can be accessed through the SEC website. In other news, insider Pamela Esposito sold 3,507 shares of the firm's stock in a transaction dated Monday, May 16th. The shares were sold at an average price of $14.59, for a total value of $51,167.13. Following the transaction, the insider now directly owns 229,402 shares of the company's stock, valued at $3,346,975.18. The transaction was disclosed in a legal filing with the SEC, which is accessible through this link. Also, CEO Philip Astley-Sparke sold 9,632 shares of the firm's stock in a transaction dated Monday, May 16th. The stock was sold at an average price of $14.59, for a total transaction of $140,530.88. Following the completion of the transaction, the chief executive officer now directly owns 1,401,080 shares in the company, valued at $20,441,757.20. The disclosure for this sale can be found here. Over the last quarter, insiders have sold 22,899 shares of company stock worth $334,096. 23.80% of the stock is owned by company insiders.

Receive REPL Stock News and Ratings via Email

Sign-up to receive the latest news and ratings for Replimune Group and its competitors with MarketBeat's FREE daily newsletter.

REPL Stock News Headlines

Replimune: Recent Developments Strengthen Bull Thesis
Replimune Group (NASDAQ:REPL) PT Lowered to $37.00
Is Replimune Group (NASDAQ:REPL) Using Too Much Debt?
Replimune Group (NASDAQ:REPL) Stock Price Down 4%
Replimune Group, Inc. (REPL)
Analyst Ratings for Replimune Group
Replimune Group: Q3 Earnings Insights
Replimune Group, Inc. Common Stock (REPL)
See More Headlines
Receive REPL Stock News and Ratings via Email

Sign-up to receive the latest news and ratings for Replimune Group and its competitors with MarketBeat's FREE daily newsletter.

REPL Company Calendar

Last Earnings
8/04/2022
Today
8/12/2022
Next Earnings (Estimated)
11/03/2022
Fiscal Year End
3/31/2023

Industry, Sector and Symbol

Industry
Biological products, except diagnostic
Sub-Industry
N/A
Sector
Medical
Current Symbol
NASDAQ:REPL
Fax
N/A
Employees
152
Year Founded
N/A

Price Target and Rating

Average Stock Price Forecast
$46.00
High Stock Price Forecast
$60.00
Low Stock Price Forecast
$30.00
Forecasted Upside/Downside
+126.9%
Consensus Rating
Buy
Rating Score (0-4)
3.00
Research Coverage
7 Analysts

Profitability

Net Income
$-118,040,000.00
Pretax Margin
N/A

Debt

Sales & Book Value

Annual Sales
N/A
Book Value
$8.32 per share

Miscellaneous

Free Float
37,572,000
Market Cap
$999.45 million
Optionable
Not Optionable
Beta
1.98

Key Executives

  • Mr. Philip Astley-Sparke FSA (Age 51)
    CEO & Director
    Comp: $880.5k
  • Dr. Robert Coffin Ph.D. (Age 57)
    Founder, Pres, Chief R&D Officer and Director
    Comp: $785.89k
  • Ms. Tanya N. Lewis M.S. (Age 51)
    Chief Devel. Operations Officer
    Comp: $4.7k
  • Mr. Sushil Patel Ph.D. (Age 51)
    Chief Commercial Officer
    Comp: $594.58k
  • Ms. Jean M. Franchi (Age 56)
    Principal Accounting Officer, CFO, Treasurer, Sec. & Compliance Officer
  • Dr. Colin A. Love Ph.D. (Age 64)
    Chief Operating Officer
  • Dr. Pamela Esposito Ph.D. (Age 47)
    Chief Bus. Officer













REPL Stock - Frequently Asked Questions

Should I buy or sell Replimune Group stock right now?

7 Wall Street equities research analysts have issued "buy," "hold," and "sell" ratings for Replimune Group in the last year. There are currently 7 buy ratings for the stock. The consensus among Wall Street equities research analysts is that investors should "buy" REPL shares.
View REPL analyst ratings
or view top-rated stocks.

What is Replimune Group's stock price forecast for 2022?

7 brokers have issued twelve-month target prices for Replimune Group's stock. Their REPL share price forecasts range from $30.00 to $60.00. On average, they anticipate the company's stock price to reach $46.00 in the next year. This suggests a possible upside of 124.4% from the stock's current price.
View analysts price targets for REPL
or view top-rated stocks among Wall Street analysts.

How have REPL shares performed in 2022?

Replimune Group's stock was trading at $27.10 on January 1st, 2022. Since then, REPL stock has decreased by 24.4% and is now trading at $20.50.
View the best growth stocks for 2022 here
.

When is Replimune Group's next earnings date?

The company is scheduled to release its next quarterly earnings announcement on Thursday, November 3rd 2022.
View our REPL earnings forecast
.

How were Replimune Group's earnings last quarter?

Replimune Group, Inc. (NASDAQ:REPL) released its quarterly earnings results on Thursday, August, 4th. The company reported ($0.78) EPS for the quarter, missing analysts' consensus estimates of ($0.63) by $0.15.

What other stocks do shareholders of Replimune Group own?

Based on aggregate information from My MarketBeat watchlists, some companies that other Replimune Group investors own include Peabody Energy (BTU), Myovant Sciences (MYOV), Peabody Energy (BTUUQ), AVEO Pharmaceuticals (AVEO), Fate Therapeutics (FATE), Immunomedics (IMMU), Pfizer (PFE), SCYNEXIS (SCYX), Exelixis (EXEL) and Fulcrum Therapeutics (FULC).

When did Replimune Group IPO?

(REPL) raised $100 million in an initial public offering (IPO) on Friday, July 20th 2018. The company issued 6,700,000 shares at a price of $14.00-$16.00 per share. J.P. Morgan, Leerink Partners and BMO Capital Markets acted as the underwriters for the IPO.

What is Replimune Group's stock symbol?

Replimune Group trades on the NASDAQ under the ticker symbol "REPL."

Who are Replimune Group's major shareholders?

Replimune Group's stock is owned by a number of retail and institutional investors. Top institutional investors include Emerald Advisers LLC (2.23%), FMR LLC (2.21%), Frazier Life Sciences Management L.P. (1.64%), Integral Health Asset Management LLC (0.44%), Bank of Montreal Can (0.44%) and Deutsche Bank AG (0.27%). Insiders that own company stock include Colin Love, Fund Iv LP Omega, Jason P Rhodes, Jean M Franchi, Pamela Esposito, Philip Astley-Sparke and Robert Coffin.
View institutional ownership trends
.

How do I buy shares of Replimune Group?

Shares of REPL stock can be purchased through any online brokerage account. Popular online brokerages with access to the U.S. stock market include WeBull, Vanguard Brokerage Services, TD Ameritrade, E*TRADE, Robinhood, Fidelity, and Charles Schwab.
Compare Top Brokerages Here.

What is Replimune Group's stock price today?

One share of REPL stock can currently be purchased for approximately $20.50.

How much money does Replimune Group make?

Replimune Group (NASDAQ:REPL) has a market capitalization of $1.01 billion. The company earns $-118,040,000.00 in net income (profit) each year or ($2.51) on an earnings per share basis.

How many employees does Replimune Group have?

The company employs 152 workers across the globe.

How can I contact Replimune Group?

Replimune Group's mailing address is 500 Unicorn Park, WOBURN MA, 01801. The official website for the company is www.replimune.com. The company can be reached via phone at (781) 222-9600 or via email at ir@replimune.com.

This page (NASDAQ:REPL) was last updated on 8/12/2022 by MarketBeat.com Staff

MarketBeat Resources

Premium Research Tools

MarketBeat All Access subscribers can access stock screeners, the Idea Engine, data export tools, research reports, and other premium tools.

Discover All Access

Market Data and Calendars

Looking for new stock ideas? Want to see which stocks are moving? View our full suite of financial calendars and market data tables, all for free.

View Market Data

Investing Education and Resources

Receive a free world-class investing education from MarketBeat. Learn about financial terms, types of investments, trading strategies and more.

Financial Terms
Details Here
MarketBeat - Stock Market News and Research Tools logo

MarketBeat empowers individual investors to make better trading decisions by providing real-time financial data and objective market analysis. Whether you’re looking for analyst ratings, corporate buybacks, dividends, earnings, economic reports, financials, insider trades, IPOs, SEC filings or stock splits, MarketBeat has the objective information you need to analyze any stock. Learn more about MarketBeat.

MarketBeat is accredited by the Better Business Bureau MarketBeat is rated as Great on TrustPilot

© American Consumer News, LLC dba MarketBeat® 2010-2022. All rights reserved.
326 E 8th St #105, Sioux Falls, SD 57103 | contact@marketbeat.com | (844) 978-6257
MarketBeat does not provide personalized financial advice and does not issue recommendations or offers to buy stock or sell any security.

Our Accessibility Statement | Terms of Service | Privacy Policy | Do Not Sell My Information | RSS Feeds

© 2022 Market data provided is at least 10-minutes delayed and hosted by Barchart Solutions. Information is provided 'as-is' and solely for informational purposes, not for trading purposes or advice, and is delayed. To see all exchange delays and terms of use please see Barchart's disclaimer.